Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

AXSM Axsome Therapeutics Inc

74,88

0,69 (0,93%)

Zuletzt aktualisiert: 17:26:15

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Axsome Therapeutics Charts.

Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Axsome Therapeutics Charts.

News Axsome Therapeutics Inc

Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Mittwoch 1 Mai 2024 (2 Tage vor) • GlobeNewswire Inc.

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Montag 15 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Mittwoch 10 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Montag 1 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Montag 25 März 2024 (1 Monat vor) • GlobeNewswire Inc.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Montag 25 März 2024 (1 Monat vor) • GlobeNewswire Inc.

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Dienstag 19 März 2024 (1 Monat vor) • GlobeNewswire Inc.

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Dienstag 5 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 1 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 1 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 29 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Dienstag 27 Februar 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Axsome Therapeutics Inc News-Artikel

Deutsche Telekom

Deutsche Lufthansa

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen